NCT00302653View on ClinicalTrials.gov

Rasburicase in Tumor Lysis Syndrome

PHASE4CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2006

Conditions

Hyperuricemia

Interventions

DRUG

Rasburicase

Rasburicase 0,20mg/Kg/Day once a day 3-7 days

Trial Locations (1)

Unknown

Sanofi-aventis administrative office, São Paulo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00302653 - Rasburicase in Tumor Lysis Syndrome | Biotech Hunter | Biotech Hunter